DAXsubsector Multi Utilites Performance (I1UD)
DBI
News
Market Data
Register to chat with like-minded investors on our interactive forums.
The “Believe it!” Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA...
By Colin Kellaher Shares of Forma Therapeutics Holdings Inc. took flight Thursday after the clinical-stage biopharmaceutical company agreed to be acquired by Denmark's Novo Nordisk AS for...
By Colin Kellaher Novo Nordisk AS on Thursday said it agreed to buy clinical-stage biopharmaceutical company Forma Therapeutics Holdings Inc. for about $1.1 billion in a deal that expands the...
Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for...
Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive...
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid...
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers...
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today...
Agustín Melián, M.D. to be named Executive Vice President, Head of Research and Development and Linea Aspesi to be named Senior Vice President, Chief Human Resources Officer Appointments...
Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD) Study design for the Phase 2 Gladiolus Study of etavopivat in patients with...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 7.46 | 2.47224523612 | 301.75 | 309.21 | 301.75 | 0 | 0 | IX |
| 4 | 15.11 | 5.1377082625 | 294.1 | 309.21 | 292.12 | 0 | 0 | IX |
| 12 | 10.92 | 3.66086694157 | 298.29 | 313.42 | 290.06 | 0 | 0 | IX |
| 26 | 14.45 | 4.90229339123 | 294.76 | 313.42 | 268.53 | 0 | 0 | IX |
| 52 | 6.36 | 2.10004952947 | 302.85 | 326.47 | 265.29 | 0 | 0 | IX |
| 156 | 58.44 | 23.3042229932 | 250.77 | 326.47 | 234.73 | 0 | 0 | IX |
| 260 | 109.13 | 54.5431827269 | 200.08 | 326.47 | 173.03 | 0 | 0 | IX |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
